In this study, combined with the results of network pharmacology and molecular docking, we speculate that the mechanism of PSP therapy for breast cancers may be related to the promotion of apoptosis and inhibition of tumor growth by targeting JAK2-STAT3 signaling pathway. Here, STAT3 is linked to breast cancer.